BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 16400637)

  • 1. Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recurrence after radical prostatectomy.
    Steuber T; Erbersdobler A; Graefen M; Haese A; Huland H; Karakiewicz PI
    Cancer; 2006 Feb; 106(4):775-82. PubMed ID: 16400637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy.
    Chun FK; Briganti A; Lebeau T; Fradet V; Steuber T; Walz J; Schlomm T; Eichelberg C; Haese A; Erbersdobler A; McCormack M; Perrotte P; Graefen M; Huland H; Karakiewicz PI
    Eur Urol; 2006 Feb; 49(2):273-8; discussion 278-9. PubMed ID: 16413103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
    Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
    Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease.
    Han M; Walsh PC; Partin AW; Rodriguez R
    J Urol; 2000 Jul; 164(1):89-92. PubMed ID: 10840430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of surgical margin status for biochemical recurrence following radical prostatectomy.
    Hashimoto K; Masumori N; Takei F; Fukuta F; Takahashi A; Itoh N; Hasegawa T; Tsukamoto T
    Jpn J Clin Oncol; 2008 Jan; 38(1):31-5. PubMed ID: 18203710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b.
    Freedland SJ; Partin AW; Epstein JI; Walsh PC
    Cancer; 2004 Apr; 100(8):1646-9. PubMed ID: 15073852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy.
    Lowe BA; Lieberman SF
    J Urol; 1997 Oct; 158(4):1452-6. PubMed ID: 9302141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy.
    Khan MA; Walsh PC; Miller MC; Bales WD; Epstein JI; Mangold LA; Partin AW; Veltri RW
    Cancer; 2003 Dec; 98(12):2583-91. PubMed ID: 14669277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy.
    Salonia A; Gallina A; Briganti A; Zanni G; Suardi N; Capitanio U; Colombo R; Bertini R; Freschi M; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2011 Apr; 107(8):1243-9. PubMed ID: 20883480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy.
    Secin FP; Bianco FJ; Vickers AJ; Reuter V; Wheeler T; Fearn PA; Eastham JA; Scardino PT
    Cancer; 2006 Jun; 106(11):2369-75. PubMed ID: 16649221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
    van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
    BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer.
    Merrill MM; Lane BR; Reuther AM; Zhou M; Magi-Galluzzi C; Klein EA
    Urology; 2007 Aug; 70(2):294-8. PubMed ID: 17826492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels.
    Freedland SJ; Aronson WJ; Kane CJ; Terris MK; Presti JC; Trock B; Amling CL
    Cancer; 2004 Aug; 101(4):748-53. PubMed ID: 15305405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated seminal vesicle invasion imparts better outcomes after radical retropubic prostatectomy for clinically localized prostate cancer: prognostic stratification of pt3b disease by nodal and margin status.
    Masterson TA; Pettus JA; Middleton RG; Stephenson RA
    Urology; 2005 Jul; 66(1):152-5. PubMed ID: 15992904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.
    Walz J; Chun FK; Klein EA; Reuther A; Graefen M; Huland H; Karakiewicz PI
    Eur Urol; 2009 Feb; 55(2):412-19. PubMed ID: 19027223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy.
    Kordan Y; Chang SS; Salem S; Cookson MS; Clark PE; Davis R; Herrell SD; Baumgartner R; Phillips S; Smith JA; Barocas DA
    J Urol; 2009 Nov; 182(5):2291-5. PubMed ID: 19758638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
    Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
    BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.